Hot Stocks in Action: Facebook, Inc. (NASDAQ:FB), Ventas, Inc. (NYSE:VTR), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Facebook, Inc. (NASDAQ:FB) reported that it had argued that traditional search warrants ought not apply in the same way to its information since the firm must actually retrieve data on behalf of police, the New York Times explained, but the panel unanimously rejected that argument. Instead, the court ruled, only defendants can challenge those warrants and only during a pretrial hearing, during which evidence might be deemed off-limits due to being gathered in an improper search. While the court seemingly issued a resounding defeat for Facebook, saying that a judge is the “constitutional gatekeeper”, as quoted in Bloomberg’s report, the ruling was not a full-throated endorsement of Vance’s tactics. Facebook, Inc. (NASDAQ:FB) reported a decrease of -1.66% to close at $95.43. The stock is going forward its 52-week low with 37.09% and moving down from its 52-week high price with -3.84%.

Ventas, Inc. (NYSE:VTR) released that its funds from operations or FFO, for the second quarter of 2015 rose to $389.0 million or $1.16 per share from $315.8 million or $1.07 per share in the prior year. Ventas currently expects its 2015 normalized FFO per share to increase to a range between $4.70 and $4.76. This updated guidance range represents five to six percent growth in normalized FFO per share over 2014. Analysts expect annual earnings of $4.66 per share. Ventas currently expects its 2015 normalized FFO per share to increase to a range between $4.70 and $4.76. This updated guidance range represents five to six percent growth in normalized FFO per share over 2014. Analysts expect annual earnings of $4.66 per share. Shares of Ventas, Inc. (NYSE:VTR) traded at $63.65 by plunging -0.98% with price volatility of 0.92% for a week and 1.46% for a month. Its beta stands at 0.38 times.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi released that the European Medicine Agency’s or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its authorization for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). The European Commission is predictable to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September. The effect of Praluent on cardiovascular morofferity and mortality has not been determined. The most ordinary adverse reactions were injection site reactions, upper respiratory tract signs and symptoms, and pruritus. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported a loss of -0.05% to close at $556.27. The total market capitalization remained 56.90 Billion, total volume of 490137 shares held in the session was surprisingly higher than its average volume of 740.23 shares.